Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers

Autor: Lukkana Suksanpaisan, Rong Xu, Mulu Z. Tesfay, Carolyn Bomidi, Stefan Hamm, Rianna Vandergaast, Nathan Jenks, Michael B. Steele, Ayuko Ota-Setlik, Hinna Akhtar, Amara Luckay, Rebecca Nowak, Kah Whye Peng, John H. Eldridge, David K. Clarke, Stephen J. Russell, Rosa Maria Diaz

Publikováno v: Molecular Therapy: Oncolytics, Vol 10, Iss , Pp 1-13 (2018)

Immunotherapy for HPVPOS malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 antigens have been adopted, including viral platforms suc

Externí odkaz: https://doaj.org/article/3396dace4a2548be8e2c17cb86f01e32

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Autor: Bernadette Jesionek, Charles Tan, Christoph Kröner, Jennifer Obregon, Stephanie Hein, Kathleen M. Brasky, Andreas Kuhn, Leyla Fischer, Guy Singh, Diana Schneider, Kathrin U. Jansen, Jane Fontenot, Seungil Han, Michal Gazi, Corinna Rosenbaum, Ingrid L. Scully, Pei Yong Shi, Parag Sahasrabudhe, Stefanie A. Krumm, Hanna Junginger, Camila R. Fontes-Garfias, Julia Schlereth, Bonny Gaby Lui, Mathias Vormehr, Andre P. Heinen, Alptekin Güler, Stephanie Fesser, Sarah C. Dany, Ellene H. Mashalidis, Danka Pavliakova, Shambhunath Choudhary, Mohan S. Maddur, Petra Adams-Quack, Yvonne Feuchter, Matthew C. Griffor, Ferdia Bates, Ramón de la Caridad Güimil Garcia, Tara Ciolino, Özlem Türeci, Stefan Schille, Kena A. Swanson, Kerstin C. Walzer, Alexander Muik, Jakob Loschko, Ayuko Ota-Setlik, Nicole L. Nedoma, Lena M. Kranz, Tompkins Kristin Rachael, Thorsten Klamp, Ugur Sahin, Ann Kathrin Wallisch, Warren Kalina, Olga Gonzalez, Fulvia Vascotto, Philip R. Dormitzer, Ye Che, Kendra J. Alfson, Ricardo Carrion, Thomas Ziegenhals, Shannan Hall-Ursone, Rani S. Sellers, Thomas Hiller, Isis Kanevsky, Matthew R. Gutman, Michael W. Pride, Stephanie Erbar, Bianca Sänger, Deepak Kaushal, Journey Cole, David Eisel, Andreas A.H. Su, Joshua A. Lees, Annette B. Vogel, Arianne Plaschke

Publikováno v: Nature

A safe and effective vaccine against COVID-19 is urgently needed in quantities that are sufficient to immunize large populations. Here we report the preclinical development of two vaccine candidates (BNT162b1 and BNT162b2) that contain nucleoside-mod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3903ab0fb32c26fb7ed5bc8fa70296ed
https://doi.org/10.1038/s41586-021-03275-y

BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2

Autor: Oezlem Tuereci, Arianne Plaschke, Tompkins Kristin Rachael, Andre P. Heinen, Joshua A. Lees, Stefan Schille, Kena A. Swanson, Deepak Kaushal, Kathrin U. Jansen, Corinna Rosenbaum, Danka Pavliakova, Ugur Sahin, Shannan Hall-Ursone, Rani S. Sellers, Journey Cole, Parag Sahasrabudhe, Stefanie A. Krumm, Ferdia Bates, Stephanie Erbar, Isis Kanevsky, Bianca Saenger, Michal Gazi, Annette B. Vogel, Kathleen M. Brasky, Matthew R. Gutman, Hanna Junginger, Sarah C. Dany, Nicole L. Nedoma, Lena M. Kranz, Camila R. Fontes-Garfias, Julia Schlereth, Shambhunath Choudhary, Andreas A.H. Su, Ramon de la Caridad Gueimil Garcia, Seungil Han, Thorsten Klamp, Ayuko Ota-Setlik, Bonny Gaby Lui, Michael W. Pride, Fulvia Vascotto, Ann-Kathrin Wallisch, Ingrid L. Scully, Stephanie Hein, David Eisel, Charles Tan, Pei Yong Shi, Mathias Vormehr, Philip R. Dormitzer, Olga Gonzalez, Kendra J. Alfson, Thomas Hiller, Bernadette Jesionek, Thomas Ziegenhals, Stephanie Fesser, Jennifer Obregon, Petra Adams-Quack, Matthew C. Griffor, Alptekin Gueler, Yvonne Feuchter, Alexander Muik, Jakob Loschko, Jane Fontenot, Christoph Kroener, Ricardo Carrion, Leyla Fischer, Warren Kalina, Andreas N. Kuhn, Ye Che, Guy Singh, Diana Schneider, Mohan S. Maddur, Kerstin C. Walzer, Tara Ciolino, Ellene H. Mashalidis

A safe and effective vaccine against COVID-19 is urgently needed in quantities sufficient to immunise large populations. We report the preclinical development of two BNT162b vaccine candidates, which contain lipid-nanoparticle (LNP) formulated nucleo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b00b93d3b666e0e3993b1b7ab468149
https://doi.org/10.1101/2020.12.11.421008

Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial

Autor: David K. Clarke, Theresa E. Latham, Michael A. Egan, Amara Luckay, Lucy A. Ward, Ayuko Ota-Setlik, Terry J. Higgins, Tracy Chen, Rong Xu, Janice M. Rusnak, Marc Tremblay, Susan E. Witko, Demetrius Matassov, Susan Sciotto-Brown, Luz Hermida, Cheryl S. Gerardi, John H. Eldridge

Publikováno v: The Lancet. Infectious diseases. 20(4)

Summary Background The safety and immunogenicity of a highly attenuated recombinant vesicular stomatitis virus (rVSV) expressing HIV-1 gag (rVSVN4CT1-HIV-1gag1) was shown in previous phase 1 clinical studies. An rVSV vector expressing Ebola virus gly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81da33fefbeb1d50c33bf76755e0d37
https://pubmed.ncbi.nlm.nih.gov/31952924

Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus

Autor: Rong Xu, Karla A. Fenton, Ayuko Ota-Setlik, Krystle N. Agans, John H. Eldridge, Chad E. Mire, Demetrius Matassov, Theresa E. Latham, David K. Clarke, Michael A. Egan, Thomas W. Geisbert, Joan B. Geisbert

Publikováno v: Nature

The family Filoviridae contains three genera, Ebolavirus (EBOV), Marburg virus, and Cuevavirus1. Some members of the EBOV genus, including Zaire ebolavirus (ZEBOV), can cause lethal hemorrhagic fever in humans. During 2014 an unprecedented ZEBOV outb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f128ddf9358c895ead849ad2cfd2fb0
https://doi.org/10.1038/nature14428